FindTrial
Sign In

Hyperbaric Oxygen Therapy Rapidly Modulates Immune Aging in a Personalized Manner: A Linear Mixed-Effects Analysis

Research on the effect of hyperbaric oxygen therapy on increasing telomere length and T cell aging

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110103
Enrollment
Unknown
Registered
2025-09-30
Start date
2022-01-11
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging

Interventions

hyperbaric oxygen therapy group:NA

Sponsors

China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 79 Years

Inclusion criteria

Inclusion criteria: (1) Diagnose patients with harmful gas poisoning and hearing loss and tinnitus (if recruitment is not successful, try expanding the disease range); (2) Patients who receive hyperbaric oxygen therapy more than 5 times;

Exclusion criteria

Exclusion criteria: (1) Received hyperbaric oxygen therapy in the past 3 months; (2) The frequency of hyperbaric oxygen therapy is less than 5 times; (3) Contraindications for hyperbaric oxygen therapy such as pulmonary bullae and multiple rib fractures If any one of the above three conditions is met, one cannot participate in the experimental team.

Design outcomes

Primary

MeasureTime frame
Telomere length;Senescent T cell;—

Countries

China

Contacts

Public ContactWang Zhenning

China Medical University

639511937@qq.com+86 139 9889 1377

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 9, 2026